ClinicalTrials.gg
CompletedNCT07588646Updated May 15, 2026

Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects

A Phase 1 interventional study of HEC585 and Nintedanib in Idiopathic Pulmonary Fibrosis, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2021, 4 years 11 months ago, and no results have been posted to the registry.
  • Registered 9 months after the study started (first participant enrolled Jun 2021, registered Mar 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis — 1 open to participants now, 1 under way, none of them phase 3. nintedanib · Idiopathic Pulmonary Fibrosis.

Enrollment
11th of 16
33 · median 49
Started
2021
with 2 others
Phase 1
6 of 16
none open now
Registered
11th of 16
by date
Lead sponsor
2 of 16
Sunshine Lake Pharma Co., Ltd.

Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, this one is the 11th largest by enrollment, is one of 3 that started in 2021, is one of 6 in phase 1, and was the 11th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis is open now. Recruiting first, the newest first:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

A single-center, open-label study designed to assess the drug-drug interaction of HEC585 and pirfenidone in healthy male and female subjects. A single-center, open-label study designed to assess the drug-drug interaction of HEC585 and nintedanib in healthy male subjects.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are willing and are able to provide a written to participate in the study.
  • Without Plann for pregnant or sperm/egg donation plan, and voluntary effective measures during the trial period and within 3 months after the last dose.
  • Subjects aged between 18 and 45 (both inclusive) years old.
  • The first part of the study included male and female subjects, and the second part of the study included only male subjects.
  • Healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and ≥19 and ≤28 kg/m2 at screening.
  • Subjects, who are healthy, as having no abnormalities in vital signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead (ECG).

Exclusion criteria

Exclusion Criteria:

  • Subjects with a positive serology for surface antigen (HBsAg), virus (HCV) antibodies, (HIV) antibodies and/or TP antibodies at screening.
  • Subjects suffering from gastrointestinal diseases that can interfere with absorption or metabolism of drugs within 6 months before screening; and/or with history of central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, immune system (such as thymus disease), reproductive system (such as prostate, testis, epididymis, ovarian disease); and/or mental illness.
  • Subjects with photosensitivity and/or other skin diseases.
  • Subjects with Bleeding risk.
  • Subjects with known allergic history or constitution to peanuts, soybeans, study drugs or any of their components.
  • Take any prescription or non-prescription medications within 14 days prior to initial dosing, or take any medications known to inhibit or induce cytochrome P enzyme drug metabolism within 28 days prior to initial dosing.
  • Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit within 48 hours prior to initial dosing.
  • Positive results from urine drug screen test.
  • History of alcoholism or drink regularly within 3 months prior to the study(defined as Alcohol consumption of > 21 units/week), or positive results from alcohol breath test.
  • For the first part of the study, subjects who had positive urine cotinine test or had smoked within 1 month before administration; for the second part of the study, subjects who had smoked more than 10 cigarettes per day within 3 months before administration.
  • Donate blood or lose blood 400 mL or more within 3 months prior to initial dosing.
  • Subjects who plan to receive or have had organ transplants.
  • Females who are lactating/breastfeeding, or positive result from pregnancy test for women of .
  • Subjects who participated in the other clinical trial within 3 months prior to initial dosing.
  • Others conditions that are not suitable for clinical trial participation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    HEC585 and Pirfenidone

    The DDI study of HEC585 and Pirfenidone

    Drug: HEC585 · Drug: Pirfenidone

  • Experimental
    HEC585 and Nintedanib

    The DDI study of HEC585 and Nintedanib

    Drug: HEC585 · Drug: Nintedanib

Interventions

  • DrugHEC585

    DDI of HEC585 and Pirfenidone:HEC585, once daily,D5-D14 and D18-D27; DDI of HEC585 and Nintedanib:HEC585,once daily,D14-D23 and D27-D36

  • DDI of HEC585 andNintedanib:Nintedanib,twice a day,D1-D7 and D30-D36

  • DDI of HEC583 and Pirfenidone: Pirfenidone:three times a day,D1-D3 and D25-D27

06

What researchers measure

Primary outcomes

  1. Area under the curve from 0 to 24 hours [AUC (0~24)]

    Area under the curve from 0 to 24 hours under steady-state conditions for HEC585 and Pirfenidone

    Time frame: Day 3 for Pirfenidone monotherapy phase; Day 14 for HEC585 monotherapy phase; Day 27 for Combination phase.

  2. Maximum Plasma Concentration (Cmax)

    Maximum Observed Plasma Concentration under steady-state conditions for Pirfenidone and HEC585

    Time frame: Day 3 for Pirfenidone monotherapy phase; Day 14 for HEC585 monotherapy phase; Day 27 for Combination phase.

  3. Area under the curve from 0 to 24 hours [AUC (0~24)]

    Area under the curve from 0 to 24 hours under steady-state conditions for HEC585 and Nintedanib

    Time frame: Day 7 for Nintedanib monotherapy phase; Day 23 for HEC585 monotherapy phase; Day 36 for Combination phase.

  4. Observed Plasma Concentration (Cmax)

    Observed Plasma Concentration under steady-state conditions for HEC585 and Nintedanib

    Time frame: Day 7 for Nintedanib monotherapy phase; Day 23 for HEC585 monotherapy phase; Day 36 for Combination phase.

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Incidence of treatment-emergent adverse events (TEAEs)assessed by CTCAE V5.0

    Time frame: up to 31 days(HEC585 and Pirfenidone)

  2. Incidence of treatment-emergent adverse events (TEAEs)

    Incidence of treatment-emergent adverse events (TEAEs)assessed by CTCAE V5.0

    Time frame: up to 40 days(HEC585 and Nintedanib)

07

Study locations

1 site
  • Shanghai Xuhui Central Hospital
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Nov 2021, 5 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2022
First posted
May 15, 2026
StartActual
Jun 29, 2021
Primary completionActual
Nov 30, 2021
CompletionActual
Nov 30, 2021
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07588646
Responsible party
Sponsor
First posted
May 15, 2026
Start date
Jun 29, 2021
Primary completion
Nov 30, 2021
Completion
Nov 30, 2021
Last update
May 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Yinfenidone · Nintedanib · Pirfenidone

Start the discussion